Gonads Exposure to Scattered Radiationand Associated Second Cancer Risk From Pelvic Radiotherapy
-
Shiva Rahbar Yazdi
,
Saman Dalvand
,
Mohammad Ali Broomand
,
Hamed Zamani
,
Mohammad Hosein Zare
,
Hamidreza Masjedi
Abstract
Purpose: The purpose of this study was to evaluate the risk of gonad cancer induction attributable to pelvic radiation therapy in adult patients.
Methods: By characterizing the peripheral dose the TLDs were placed on the testis and ovary in two fractions of radiotherapy. All patients delivered a 45 Gy total dose in 4 fields in the prone position with 3D planning. The doses from a linear accelerator at 18 MV photon beam, were investigated.
Results: The mean excess relative risk (ERR) based on the BEIR IIV models of men and women after 5 and 10 year of radiotherapy treatment for pelvic radiotherapy was 0.825±0.168, 0.948±0.504, 0.700±0.135, and 0.803±0.407 respectively.
Conclusion: Estimating the second cancer risk of untargeted organs is crucial in radiotherapy. Using the single-energy mode linear accelerator and proper shields can be minimized the out-of-field doses.
1- L.M Burt, J Ying, M.M Poppe, G Suneja, and D.K Gaffney, "Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results." The Breast, Vol. 35pp. 9-122, (2017).
2- L.M Morton, K Onel, R.E Curtis, E.A Hungate, and G.T Armstrong, "The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults." American Society of Clinical Oncology Educational Book, Vol. 34 (No. 1), pp. 57-67, (2014).
3- A.B De Gonzalez et al., "Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries." The lancet oncology, Vol. 12 (No. 4), pp. 60-353, (2011).
4- J Ferlay et al., "Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods." International journal of cancer, Vol. 144 (No. 8), pp. 53-1941, (2019).
5- L Feller and J Lemmer, "New'second primary'cancers." South African Dental Journal, Vol. 67 (No. 4), pp. 8-175, (2012).
6- F Difilippo et al., "Contamination dose from photoneutron processes in bodily tissues during therapeutic radiation delivery." Medical physics, Vol. 30 (No. 10), pp. 54-2849, (2003).
7- C Hamilton, A Horwich, J Bliss, and M Peckham, "Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis." Radiotherapy and Oncology, Vol. 10 (No. 2), pp. 85-90, (1987).
8- A.K Chaturvedi et al., "Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk." Journal of the National Cancer Institute, Vol. 99 (No. 21), pp. 43-1634, (2007).
9- A.J Rombouts, N Hugen, M.A Elferink, P.M Poortmans, I.D Nagtegaal, and J.H de Wilt, "Increased risk for second primary rectal cancer after pelvic radiation therapy." European Journal of Cancer, Vol. 124pp. 51-142, (2020).
10- National Research Council, Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2.
11- J Azorín Nieto, "editor Thermoluminescence dosimetry (TLD) and its application in medical physics." AIP conference proceedings, Vol. 724 (No. 1), pp. 20-27, (2004).
12- P Hauri, "Out-of-field dose in photon radiotherapy: models and measurements measurements (Doctoral dissertation)." University of Zurich, (2017).
13- A.P Andersen, "Postoperative irradiation of glioblastomas: results in a randomized series." Acta radiologica: oncology, radiation, physics, biology, Vol. 17 (No. 6), pp. 84-475, (1978).
14- S Liauw, J Sylvester, C Morris, J Blasko, and P Grimm, "Second Malignancies After Prostate Brachytherapy: Incidence of Bladder and Colorectal Cancers in Patients With 15 Years of Potential Follow-up." International Journal of Radiation Oncology, Biology, Physics, Vol. 66 (No. 3), pp. 1-390, (2006).
15- H Nikbakht et al., "Latency and interval therapy affect the evolution in metastatic colorectal cancer." Scientific reports, Vol. 10 (No. 1), pp. 1-10, (2020).
16- J Halamkova et al., "Second primary malignancies in colorectal cancer patients." Scientific reports, Vol. 11 (No. 1), pp. 1-12, (2021).
17- F Abolaban and F Djouider, "Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia." (2021).
18- SE Kim, HY Paik, H Yoon, JE Lee, N Kim, and MK Sung, "Sex-and gender-specific disparities in colorectal cancer risk." World journal of gastroenterology: WJG, Vol. 21 (No. 17), pp. 51-67, (2015).
19- M Mazonakis, J Damilakis, H Varveris, and N Gourtsouiannis, "Radiation dose to testes and risk of infertility from radiotherapy for rectal cancer." Oncology reports, Vol. 15 (No. 3), pp. 33-729, (2006).
20- N Ahmadlou et al., "Impact of scattered radiation on testosterone deficiency and male hypogonadism in rectal cancer treated with external beam pelvic irradiation." Middle East Journal of Cancer, Vol. 1 (No. 3), pp. 115-22, (2010).
21- RM Hermann et al., "Testicular dose and hormonal changes after radiotherapy of rectal cancer." Radiotherapy and Oncology, Vol. 75 (No. 1), pp. 8-83, (2005).
22- P Haddad, Z Karimi-Moghaddam, M Esfahani, M Afkhami, F Farhan, and F Amouzegar-Hashemi, "Thermoluminescence dosimetry of the dose received by scrotum and testes in radiotherapy of rectal cancer, compared to the point doses calculated by 3D-planning software." Physica Medica, Vol. 1 (No. 45), pp. 5-143, (2018).
2- L.M Morton, K Onel, R.E Curtis, E.A Hungate, and G.T Armstrong, "The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults." American Society of Clinical Oncology Educational Book, Vol. 34 (No. 1), pp. 57-67, (2014).
3- A.B De Gonzalez et al., "Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries." The lancet oncology, Vol. 12 (No. 4), pp. 60-353, (2011).
4- J Ferlay et al., "Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods." International journal of cancer, Vol. 144 (No. 8), pp. 53-1941, (2019).
5- L Feller and J Lemmer, "New'second primary'cancers." South African Dental Journal, Vol. 67 (No. 4), pp. 8-175, (2012).
6- F Difilippo et al., "Contamination dose from photoneutron processes in bodily tissues during therapeutic radiation delivery." Medical physics, Vol. 30 (No. 10), pp. 54-2849, (2003).
7- C Hamilton, A Horwich, J Bliss, and M Peckham, "Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis." Radiotherapy and Oncology, Vol. 10 (No. 2), pp. 85-90, (1987).
8- A.K Chaturvedi et al., "Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk." Journal of the National Cancer Institute, Vol. 99 (No. 21), pp. 43-1634, (2007).
9- A.J Rombouts, N Hugen, M.A Elferink, P.M Poortmans, I.D Nagtegaal, and J.H de Wilt, "Increased risk for second primary rectal cancer after pelvic radiation therapy." European Journal of Cancer, Vol. 124pp. 51-142, (2020).
10- National Research Council, Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2.
11- J Azorín Nieto, "editor Thermoluminescence dosimetry (TLD) and its application in medical physics." AIP conference proceedings, Vol. 724 (No. 1), pp. 20-27, (2004).
12- P Hauri, "Out-of-field dose in photon radiotherapy: models and measurements measurements (Doctoral dissertation)." University of Zurich, (2017).
13- A.P Andersen, "Postoperative irradiation of glioblastomas: results in a randomized series." Acta radiologica: oncology, radiation, physics, biology, Vol. 17 (No. 6), pp. 84-475, (1978).
14- S Liauw, J Sylvester, C Morris, J Blasko, and P Grimm, "Second Malignancies After Prostate Brachytherapy: Incidence of Bladder and Colorectal Cancers in Patients With 15 Years of Potential Follow-up." International Journal of Radiation Oncology, Biology, Physics, Vol. 66 (No. 3), pp. 1-390, (2006).
15- H Nikbakht et al., "Latency and interval therapy affect the evolution in metastatic colorectal cancer." Scientific reports, Vol. 10 (No. 1), pp. 1-10, (2020).
16- J Halamkova et al., "Second primary malignancies in colorectal cancer patients." Scientific reports, Vol. 11 (No. 1), pp. 1-12, (2021).
17- F Abolaban and F Djouider, "Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia." (2021).
18- SE Kim, HY Paik, H Yoon, JE Lee, N Kim, and MK Sung, "Sex-and gender-specific disparities in colorectal cancer risk." World journal of gastroenterology: WJG, Vol. 21 (No. 17), pp. 51-67, (2015).
19- M Mazonakis, J Damilakis, H Varveris, and N Gourtsouiannis, "Radiation dose to testes and risk of infertility from radiotherapy for rectal cancer." Oncology reports, Vol. 15 (No. 3), pp. 33-729, (2006).
20- N Ahmadlou et al., "Impact of scattered radiation on testosterone deficiency and male hypogonadism in rectal cancer treated with external beam pelvic irradiation." Middle East Journal of Cancer, Vol. 1 (No. 3), pp. 115-22, (2010).
21- RM Hermann et al., "Testicular dose and hormonal changes after radiotherapy of rectal cancer." Radiotherapy and Oncology, Vol. 75 (No. 1), pp. 8-83, (2005).
22- P Haddad, Z Karimi-Moghaddam, M Esfahani, M Afkhami, F Farhan, and F Amouzegar-Hashemi, "Thermoluminescence dosimetry of the dose received by scrotum and testes in radiotherapy of rectal cancer, compared to the point doses calculated by 3D-planning software." Physica Medica, Vol. 1 (No. 45), pp. 5-143, (2018).
| Files | ||
| Issue | Vol 10 No 4 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/fbt.v10i4.13721 | |
| Keywords | ||
| Radiotherapy Cancer Risk Thermo Luminescence Dosimeters Organ Dose | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Rahbar Yazdi S, Dalvand S, Broomand MA, Zamani H, Zare MH, Masjedi H. Gonads Exposure to Scattered Radiationand Associated Second Cancer Risk From Pelvic Radiotherapy. Frontiers Biomed Technol. 2023;10(4):394-399.
